This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Countdown to Aveanna (AVAH) Q1 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Aveanna (AVAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Addus HomeCare (ADUS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 10% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Aveanna (AVAH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Aveanna (AVAH) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 50% and 3.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Has Aveanna Healthcare (AVAH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and Bausch Health (BHC) have performed compared to their sector so far this year.
Aveanna (AVAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
RadNet (RDNT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 133.33% and 2.74%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Aveanna (AVAH) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Aveanna (AVAH) for the quarter ended September 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Waters (WAT) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Waters' (WAT) Q3 results benefit from a strong Pharmaceutical market, as well as a strong contribution from the Wyatt acquisition.
The Pennant Group, Inc. (PNTG) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aveanna (AVAH) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aveanna Healthcare (AVAH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 50% and 4.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 242.86% and 3.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Stock Jumps 11.7%: Will It Continue to Soar?
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 16.67% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health Group (LFST) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 18.18% and 2.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -14.29% and 5.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 850% and 3.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aveanna Healthcare (AVAH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Aveanna (AVAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Option Care (OPCH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 23.53% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of -50% and 0.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 0% and 6.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Oak Street Health, Inc. (OSH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oak Street Health, Inc. (OSH) delivered earnings and revenue surprises of 9.68% and 1.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 12th
by Zacks Equity Research
APP, ACIW and ABM have been added to the Zacks Rank #5 (Strong Sell) List on January 12, 2023.
New Strong Sell Stocks for January 9th
by Zacks Equity Research
ADTN, AVAH and DBI have been added to the Zacks Rank #5 (Strong Sell) List on January 9, 2023.